Efavirenz

Generic Name: Efavirenz

Brand Names: Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₉ClF_₃NO_₂

CAS Number: 154598-52-4

Unique Ingredient Identifier: JE6H2O27P8

Background: Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.
...

Indication: For use in combination treatment of HIV infection (AIDS)

Associated Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Associated Therapies: -

Clinical Trials

Efavirenz-based Versus Nevirapine-based Antiretroviral Therapy Among HIV-infected Patients Receiving Rifampin

Phase 3

Completed

Conditions: HIV Infections
Tuberculosis

Interventions: Drug: efavirenz
Drug: nevirapine

First Posted Date: 2007-06-06

Last Posted Date: 2011-11-22

Lead Sponsor: Bamrasnaradura Infectious Diseases Institute

Target Recruit Count: 142

Registration Number: NCT00483054

Locations: 🇹🇭
Bamrasnaradura Infectious Diseases Institute, Nonthaburi, Thailand

A Pharmacokinetic Study of Once Daily Efavirenz 400 mg Versus 600 mg in Thai HIV-1 Infected Subjects

Phase 2

Completed

Conditions: HIV Infections

Interventions: Drug: efavirenz

First Posted Date: 2007-05-22

Last Posted Date: 2020-07-17

Lead Sponsor: The HIV Netherlands Australia Thailand Research Collaboration

Target Recruit Count: 28

Registration Number: NCT00476424

Locations: 🇹🇭
The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Bangkok, Thailand

Mechanisms of Lipodystrophy in HIV-Infected Pateints

Phase 4

Completed

Conditions: HIV Infections

Interventions: Drug: Efavirenz
Drug: Nelfinavir

First Posted Date: 2007-04-06

Last Posted Date: 2019-07-18

Lead Sponsor: University of Texas Southwestern Medical Center

Target Recruit Count: 56

Registration Number: NCT00457665

Locations: 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States

HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV

Phase 4

Completed

Conditions: HIV Infections

Interventions: Drug: Efavirenz
Drug: Emtricitabine/Tenofovir disoproxil fumarate

First Posted Date: 2007-03-05

Last Posted Date: 2018-10-12

Lead Sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Target Recruit Count: 54

Registration Number: NCT00442962

Locations: 🇺🇸
Ucsd, Avrc, San Diego, California, United States
🇺🇸
Brigham and Women's Hospital, Division of Infectious Disease, Boston, Massachusetts, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 6 locations

Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-naive Participants

Phase 2

Completed

Conditions: HIV Infections

Interventions: Drug: Elvucitabine
Drug: Lamivudine
Drug: Tenofovir
Drug: Efavirenz

First Posted Date: 2006-07-10

Last Posted Date: 2023-08-30

Lead Sponsor: Alexion Pharmaceuticals, Inc.

Target Recruit Count: 76

Registration Number: NCT00350272

Locations: 🇵🇷
Clinical Trial Site, San Juan, Puerto Rico

Antiretroviral Therapy for Advanced HIV Disease in South Africa

Phase 4

Completed

Conditions: HIV

Interventions: Drug: Zidovudine
Drug: Stavudine
Drug: Lamivudine
Drug: Didanosine
Drug: Lopinavir/Ritonavir
Drug: Efavirenz

First Posted Date: 2006-06-21

Last Posted Date: 2013-05-21

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 1771

Registration Number: NCT00342355

Locations: 🇿🇦
Mtubatuba SIckbay, Kwazulu-Natal, South Africa
🇿🇦
Umtata Sickbay, Eastaern Cape, South Africa
🇿🇦
South African Military Health Services (SAMHS), Centurion, South Africa

and more 4 locations

Antiretroviral Treatment Simplification Study With Efavirenz + Abacavir + 3TC Once Daily

Phase 3

Completed

Conditions: HIV Infections

Interventions: Drug: efavirenz
Drug: Abacavir+lamivudine

First Posted Date: 2006-04-14

Last Posted Date: 2008-01-29

Lead Sponsor: Germans Trias i Pujol Hospital

Target Recruit Count: 99

Registration Number: NCT00314626

Locations: 🇪🇸
Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain
🇪🇸
Hospital Costa del Sol, Marbella, Málaga, Spain
🇪🇸
Hospital de Mataró, Mataro, Barcelona, Spain

and more 13 locations

Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Nelfinavir
Drug: Saquinavir/ritonavir
Drug: Lopinavir/ritonavir
Drug: Atazanavir
Drug: Atazanavir/ritonavir
Drug: Fos-amprenavir/ritonavir
Drug: Tipranavir/ ritonavir
Drug: Darunavir/ritonavir
Drug: Nevirapine
Drug: Efavirenz
Drug: Indinavir/ritonavir

First Posted Date: 2006-03-28

Last Posted Date: 2019-12-04

Lead Sponsor: Germans Trias i Pujol Hospital

Target Recruit Count: 675

Registration Number: NCT00307502

Locations: 🇪🇸
Hospital de Figueres, Figueras, Barcelona, Spain
🇪🇸
Hospital Universitari Sant Joan de Reus, Reus, Tarragona, Spain
🇪🇸
Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain

and more 3 locations

Comparing the Effectiveness Between Ritonavir Boosted Atazanavir and Efavirenz for the First HIV Treatment

Phase 3

Completed

Conditions: HIV Infection

Interventions: Drug: atazanavir arm
Drug: efavirenz

First Posted Date: 2006-01-24

Last Posted Date: 2015-03-30

Lead Sponsor: International Medical Center of Japan

Target Recruit Count: 71

Registration Number: NCT00280969

Locations: 🇯🇵
International Medical Center of Japan, Shinjuku, Tokyo, Japan

Blood Levels of Anti-HIV Drugs Used in Combination Regimens in HIV Infected Children

Phase 1

Completed

Conditions: HIV Infections

Interventions: Drug: Efavirenz
Drug: Darunavir
Drug: Atazanavir
Drug: Nevirapine
Drug: Ritonavir
Procedure: Pharmacokinetic Study
Drug: Tenofovir disoproxil fumarate

First Posted Date: 2005-12-01

Last Posted Date: 2021-11-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 75

Registration Number: NCT00260078

Locations: 🇺🇸
Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago, Illinois, United States
🇺🇸
Ann & Robert H. Lurie Children's Hospital of Chicago (LCH) CRS, Chicago, Illinois, United States
🇺🇸
Children's Hosp. of Boston NICHD CRS, Boston, Massachusetts, United States

and more 20 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy